VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
LP-98
Phase 2
Small molecule
S
Shanxi Kangbao Biological Product Co., Ltd.
1
Indications
2
Total Trials
1
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
HIV-Infected Individuals
Recruiting
Preclinical
Phase 1
Phase 2
Phase 3
Approved
HIV-Infected Individuals
Phase 2
Recruiting
Clinical
Trials by Indication
[1]
HIV-Infected Individuals
1 trial
Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals
Recruiting
·
S
Shanxi Kangbao Biological Product Co., Ltd.
·
Phase 1/2
·
NCT07433387
·
30 enrolled
Immunogenicity
1 trial
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects
Completed
·
S
Shanxi Kangbao Biological Product Co., Ltd.
·
Phase 1
·
NCT05933824
·
36 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
2 trial records for LP-98. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
LP-98 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for LP-98. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Shanxi Kangbao Biological Product Co., Ltd. company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 2
[1]
Company
S
Shanxi Kangbao Biological Product Co., Ltd.
Related News